Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial

被引:1058
作者
Gionchetti, P
Rizzello, F
Venturi, A
Brigidi, P
Matteuzzi, D
Bazzocchi, G
Poggioli, G
Miglioli, M
Campieri, M
机构
[1] Univ Bologna, Policlin S Orsola, Dipartimento Med Interna & Gastroenterol, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Pharmaceut Sci, I-40138 Bologna, Italy
[3] Univ Bologna, Dept Clin Surg, I-40138 Bologna, Italy
关键词
D O I
10.1053/gast.2000.9370
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Pouchitis is the major long-term complication after ileal pouch-anal anastomosis for ulcerative colitis. Most patients have relapsing disease, and no maintenance treatment study has been performed. We evaluated the efficacy of a probiotic preparation (VSL#3) containing 5 x 10(11) per gram of viable lyophilized bacteria of 4 strains of lactobacilli, 3 strains of bifidobacteria, and 1 strain of Streptococcus salivarius subsp. thermophilus compared with placebo in maintenance of remission of chronic pouchitis. Methods: Forty patients in clinical and endoscopic remission were randomized to receive either VSL#3, 6 g/day, or an identical placebo for 9 months. Patients were assessed clinically every month and endoscopically and histologically every 2 months or in the case of a relapse. Fecal samples were collected for stool culture before and after antibiotic treatment and each month during maintenance treatment. Results: Three patients (15%) in the VSL#3 group had relapses within the 9-month follow-up period, compared with 20 (100%) in the placebo group (P < 0.001). Fecal concentration of lactobacilli, bifidobacteria, and S. thermophilus increased significantly from baseline levels only in the VSL#3-treated group (P < 0.01). Conclusions: These results suggest that oral administration of this new probiotic preparation is effective in preventing flare-ups of chronic pouchitis.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 30 条
[1]   Econutrition and health maintenance - A new concept to prevent GI inflammation, ulceration and sepsis [J].
Bengmark, S .
CLINICAL NUTRITION, 1996, 15 (01) :1-10
[2]   Robiotics, prebiotics or 'conbiotics'? [J].
Berg, RD .
TRENDS IN MICROBIOLOGY, 1998, 6 (03) :89-92
[3]   Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? [J].
Campieri, M ;
Gionchetti, P .
GASTROENTEROLOGY, 1999, 116 (05) :1246-1249
[4]   PROBIOTICS IN HUMAN MEDICINE [J].
FULLER, R .
GUT, 1991, 32 (04) :439-442
[5]  
Gionchetti P, 1999, GASTROENTEROLOGY, V116, pA723
[6]  
Hurst RD, 1996, ARCH SURG-CHICAGO, V131, P497
[7]   Review article: The management of pouchitis [J].
Keighley, MRB .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (04) :449-457
[8]   Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis [J].
Kruis, W ;
Schutz, E ;
Fric, P ;
Fixa, B ;
Judmaier, G ;
Stolte, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :853-858
[9]  
LOHMULLER JL, 1990, ANN SURG, V211, P622
[10]   THE NORMAL MICROBIAL-FLORA [J].
MACKOWIAK, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (02) :83-93